Glycaemic Control According to the Final Insulin Dose Using an Innovative Fixed‐Dose Titration of Weekly Insulin Efsitora in Insulin‐Naïve Type 2 Diabetes Authors: Lisa Connery, Julio Rosenstock, Neda Rasouli, Alice Y. Y. Cheng, Andreas Liebl, Qianqian Wang, Vitoria Pires, Alastair Knights, Michael B. Davidson, Christopher J. Child Published: 2026 ABSTRACT ABSTRACTAimsIn the QWINT‐1 phase 3 Trial, once‐weekly insulin efsitora alfa (efsitora) administered using an innovative fixed‐dose regimen demonstrated noninferior HbA1c reduction versus once‐daily insulin glargine U100 (glargine) over 52 weeks in insulin‐naïve adults with type 2 diabetes. This report focuses on baseline characteristics and clinical outcomes of efsitora‐treated participants based on their insulin dose at Week 52 (N = 303).MethodsEfsitora was dosed using a fixed‐dose titration regimen with 100, 150, 250 and 400 U fixed‐doses titrated as needed every 4 weeks to achieve fasting blood glucose (FBG) of 80–130 mg/dL (4.4–7.2 mmol/L). Participants not at target FBG on the 400 U fixed‐dose after ≥ 4 weeks transitioned to flexible dosing using an efsitora multi‐dose pen. Glargine was administered using a multi‐dose pen and titrated weekly to the same target. Analyses assessed clinical characteristics and glycaemic outcomes by efsitora dose at Week 52, and hypoglycaemia after fixed‐dose increases.ResultsParticipants requiring higher Week 52 efsitora doses had greater baseline weight, HbA1c and fasting glucose, and more were male. Most participants (76%) remained on a fixed efsitora dose, and the majority established their final dose by Week 16. All efsitora fixed‐doses resulted in robust HbA1c lowering, with mean final HbA1c < 7.0%. Based on events within 4‐week periods after an efsitora fixed‐dose increase, estimated rates of combined Level 2 and 3 hypoglycaemia were < 0.5 events/year.ConclusionsIn QWINT‐1, the innovative fixed‐dose efsitora simple titration resulted in effective HbA1c lowering for all fixed doses. Rates of clinically meaningful hypoglycaemia were low after fixed‐dose increases. Introduction People with type 2 diabetes (T2D) often experience significant inertia when starting and intensifying basal insulin therapy, in part due to complex basal insulin titration regimens with daily insulins [1]. Treatment inertia contributes to chronic hyperglycaemia and suboptimal glycaemic outcomes in people with T2D [2, 3]. A once‐weekly basal insulin with a straightforward fixed‐dose titration regimen may simplify insulin treatment and thereby potentially reduce therapeutic inertia seen with initiation and titration of basal insulin therapy. Insulin efsitora alfa (efsitora) is a basal insulin with a flat pharmacokinetic profile and long half‐life that allows for once‐weekly administration. The QWINT (once‐weekly [QW] insulin therapy) phase 3 programme evaluated the safety and efficacy of efsitora compared with once‐daily insulin degludec U100 (degludec) or glargine U100 (glargine) across a variety of populations [4]. The QWINT‐1 study investigated a first‐of‐its‐kind fixed dosing regimen for efsitora using 4 weekly fixed doses of 100, 150, 250 and 400 U (approximately equivalent to daily doses of 14 U, 21 U, 36 U, and 57 U, respectively) in insulin‐naïve adults with T2D [5]. Treatment with once‐weekly efsitora for 52 weeks using this fixed‐dose titration regimen resulted in similar mean glycosylated haemoglobin (HbA1c) reductions to 7.0% compared with once‐daily glargine titrated using traditional methods, along with low rates of clinically significant hypoglycaemia (< 54 mg/dL [< 3.0 mmol/L]; Level 2) or severe hypoglycaemia (requiring assistance for treatment; level 3), with less than 1 event per patient year of exposure [5]. Treatment with efsitora was associated with lower rates of clinically significant or severe hypoglycaemia versus glargine. This convenient, fixed‐dose regimen for efsitora represents a new approach to titration of basal insulin with weekly dosing and monthly titration. Given the simplicity of this regimen, and its comparable safety and efficacy with once‐daily basal insulin, use of this approach could facilitate insulin treatment and reduce injection burden compared with traditional daily basal insulin. As such, once‐weekly efsitora, administered using a fixed‐dose regimen, has the potential to reduce inertia related to initiation and titration of daily basal insulin. People with T2D and clinicians may perceive that the higher weekly doses of efsitora used in QWINT‐1 correspond to large daily basal‐insulin equivalents (multiplied the daily dose by seven to convert to weekly dosing), or to large increments in insulin dose. They may also expect these larger doses to potentially increase rates of hypoglycaemia; however, this was not observed in the QWINT‐1 trial. Therefore, it is important to examine efficacy and safety outcomes across the fixed efsitora doses. This post hoc analysis examined clinical characteristics of participants and glycaemic control across different dose subgroups as well as hypoglycaemia rates after each dose escalation. Methods Study Design The QWINT‐1 study was a phase 3, open‐label, randomised, controlled, treat‐to‐target trial conducted at 71 sites in Argentina, Mexico and the United States. The trial was conducted in accordance with the Declaration of Helsinki and the International Conference for Harmonisation Good Clinical Practice guidelines. The protocol was approved by institutional review boards at each site and all patients provided written, informed consent. The design and eligibility criteria for the QWINT‐1 study have been previously published, along with the study protocol [5]. In brief, the trial was comprised of a 3‐week screening and lead‐in period, a 52‐week treatment period and a 5‐week safety follow‐up period. Insulin‐naïve adults with T2D on stable treatment with 1–3 non‐insulin glucose‐lowering agents (N = 795) were randomised in a 1:1 ratio to receive either efsitora (n = 397) or glargine (n = 398). Randomisation was stratified by country, screening visit HbA1c (< 8.0% or ≥ 8.0%) and glucagon‐like peptide‐1 receptor agonist (GLP‐1 RA) use (yes or no). Participants in the efsitora group started on a fixed weekly dose of 100 U, with administration recommended on the same day and at approximately the same time each week using a single‐dose pen (autoinjector). Efsitora dose could be escalated after 4 weeks, as needed, to the next higher weekly dose of 150, 250 and 400 U delivered via corresponding single‐dose pens. Dose adjustments were based on the median of the 3 most recent fasting blood glucose (FBG) values from the preceding 7 days to achieve a target of 80–130 mg/dL (4.4–7.2 mmol/L) or in response to hypoglycaemia [5]. Dose reduction due to hypoglycaemia could occur at any time if a participant met at least one of the following criteria: ≥ 3 hypoglycaemic events ≤ 70 mg/dL (3.9 mmol/L), ≥ 1 hypoglycaemic event < 54 mg/dL (3.0 mmol/L), ≥ 1 nocturnal hypoglycaemic event ≤70 mg/dL (3.9 mmol/L), or any severe hypoglycaemic event (Level 3) in the preceding 7 days. Participants treated with the 400 U fixed‐dose of efsitora for at least 4 weeks who still had a median FBG > 130 mg/dL (7.2 mmol/L), without meeting the hypoglycaemia criteria, transitioned to variable doses above 400 U administered using a multi‐dose pen (KwikPen). Such transitions to flexible dosing > 400 U could occur no earlier than treatment Week 16. Assessments for efsitora dose adjustments were conducted every 4 weeks during the first 16 weeks of treatment and then thereafter at each scheduled study visit or at least every 4 weeks. If a dose reduction of a fixed‐dose of efsitora occurred due to hypoglycaemia, dose re‐escalation was not permitted through the remainder of the study. Glargine was administered once daily at approximately the same time each day using a multi‐dose pen and titrated weekly according to a traditional dosing algorithm to achieve the same fasting glucose target; dose re‐escalation was permitted after glargine dose reduction for hypoglycaemia if required to meet glycaemic target [5]. Outcomes This exploratory analysis evaluated the proportion of QWINT‐1 participants using each efsitora fixed‐dose and the efsitora multi‐dose pen throughout the study, along with characteristics and clinical outcomes for participants according to their final efsitora dose at Week 52 (N = 303). Outcomes that were assessed by dose at Week 52 included baseline demographics and characteristics of participants, HbA1c change from baseline to Week 52, FBG change from baseline to Week 52 and the proportion of participants who achieved HbA1c targets of < 7.0% and ≤ 6.5% at Week 52. Additionally, the incidence and rate of hypoglycaemia were assessed focusing on the first 16 weeks of the study (period with the majority of fixed‐dose increases) and in the 4 weeks following an efsitora fixed‐dose change. Levels of hypoglycaemia severity were Level 1 (hypoglycaemia alert; glucose ≥ 54 and < 70 mg/dL [≥ 3.0 and < 3.9 mmol/L]), Level 2 (clinically significant hypoglycaemia; glucose < 54 mg/dL [< 3.0 mmol/L]) and Level 3 (severe hypoglycaemia; requiring assistance for treatment). Statistical Analysis Dose subgroups in the efsitora group were determined according to participants' dose at Week 52 (100, 150, 250, and 400 U, and doses > 400 U using the multi‐dose pen). Participants receiving efsitora with dosing data available at Week 52 were included in subgroup analyses. As the dose subgroups were based on final doses achieved and not assigned by randomisation, analyses by dose subgroup are limited to summary statistics. Results Proportion of Efsitora‐Treated Participants on Each Dose Throughout the Study A Sankey diagram that depicts the flow of participant doses throughout the study is shown in Figure 1. For participants who completed study treatment, most remained on 1 of the fixed efsitora doses throughout the study (76%); the majority of these participants (61%) established their final dose within the first 16 weeks. Furthermore, approximately two‐thirds of participants required two or fewer dose increases over the entire 52‐week treatment period. Many of those who reached the 400 U fixed‐dose subsequently transitioned to flexible dosing of doses > 400 U with the multi‐dose pen (60%). Overall, 24% of participants transitioned to flexible efsitora doses > 400 U using the multi‐dose pen. Of the participants who transitioned to flexible dosing with the multi‐dose pen, 50% ended up on a final dose of 520 U or less and 90% ended up on a dose of 720 U or less. Proportion of participants treated with efsitora using each fixed‐dose and the multi‐dose pen throughout the study. Width of the flow between doses and bars at timepoint are proportional to the number of participants affected. Open bars represent proportion of missing dose information at timepoint. †Based on available insulin dose information at Week 52. Baseline Characteristics of Participants by Efsitora Dose at Week 52 There was a higher proportion of male compared with female participants on higher efsitora doses at Week 52 (Table 1). Participants on higher efsitora doses at Week 52 had higher baseline weight, body mass index (BMI), HbA1c and fasting glucose. The ethnicity and race of participants were similar across dose levels at Week 52. Overall, the proportion of participants using GLP‐1 RAs was relatively low (~10%); the highest rates of use of GLP‐1 RAs, dipeptidyl peptidase 4 inhibitors, sodium‐glucose cotransporter 2 inhibitors and thiazolidinediones were in the 400 U efsitora fixed‐dose group. Participant baseline characteristics are also shown for the overall glargine treatment group (Table 1). TABLE 1Baseline characteristics by efsitora dose group at Week 52 and for glargine (randomised population).ParameterInsulin efsitora alfa, dose group at Week 52Insulin glargine100 U150 U250 U400 UMulti‐dose pen (> 400 U) N 5463862773398Age (years)58.6 ± 9.359.7 ± 8.556.0 ± 9.558.0 ± 8.853.4 ± 9.756.2 ± 9.7Male sex, n (%)20 (37.0)27 (42.9)53 (61.6)17 (63.0)42 (58.9)195 (49.0)Ethnicity, n (%)Hispanic or Latino49 (90.7)52 (82.5)73 (84.9)18 (66.7)61 (83.6)336 (84.4)Not Hispanic or Latino5 (9.3)11 (17.5)13 (15.1)9 (33.3)12 (16.4)61 (15.3)Race, n (%) a American Indian or Alaskan Native18 (33.3)19 (30.2)24 (27.9)8 (29.6)13 (17.8)107 (27.0)Asian02 (3.2)001 (1.4)6 (1.5)Black or African American02 (3.2)3 (3.5)1 (3.7)2 (2.7)10 (2.5)White36 (66.7)40 (63.5)59 (68.6)17 (63.0)56 (76.7)272 (68.5)Multiple0001 (3.7)1 (1.4)1 (0.3)RegionArgentina23 (42.6)26 (41.3)36 (41.9)9 (33.3)37 (50.7)171 (43.0)Mexico23 (42.6)21 (33.3)31 (36.0)8 (29.6)13 (17.8)129 (32.4)United States8 (14.8)16 (25.4)19 (22.1)10 (37.0)23 (31.5)98 (24.6)Weight (kg)78.9 ± 19.183.9 ± 15.991.0 ± 19.6100.2 ± 17.198.1 ± 17.085.5 ± 19.7BMI (kg/m2)30.3 ± 6.431.3 ± 5.432.1 ± 5.435.6 ± 5.234.8 ± 5.031.3 ± 6.1Diabetes duration (years)11.0 ± 7.710.2 ± 7.18.1 ± 5.99.7 ± 8.28.2 ± 5.39.6 ± 6.9HbA1c (%)7.8 ± 0.78.0 ± 0.88.3 ± 0.98.3 ± 0.98.4 ± 0.88.3 ± 1.1FSG (mg/dL) b 131 ± 28153 ± 42165 ± 46176 ± 53169 ± 44161.1 ± 51.8Non‐insulin glucose‐lowering agents, n (%)Metformin50 (92.6)61 (96.8)81 (94.2)24 (88.9)67 (91.8)370 (93.0)DPP‐4 inhibitors20 (37.0)18 (28.6)27 (31.4)14 (51.9)27 (37.0)121 (30.4)SGLT2 inhibitors15 (27.8)16 (25.4)20 (23.3)8 (29.6)14 (19.2)91 (22.9)GLP‐1 RA5 (9.3)7 (11.1)11 (12.8)6 (22.2)4 (5.5)38 (9.5)Thiazolidinedione4 (7.4)5 (7.9)5 (5.8)3 (11.1)1 (1.4)20 (5.0) Note: Data are mean ± standard deviation unless specified otherwise.Abbreviations: BMI = body mass index, DPP‐4 = dipeptidyl peptidase 4, FSG = fasting serum glucose, GLP‐1 RA = glucagon‐like peptide‐1 receptor agonist, HbA1c = glycosylated haemoglobin, N = number of participants with available dose data at Week 52 for efsitora and overall participants randomised to glargine, SGLT2 = sodium‐glucose cotransporter 2. a Race category percentages may not add to 100% as responses of ‘Native Hawaiian/other Pacific Islander’ and ‘Missing’ are not included. b FSG was measured at baseline by the central laboratory; self‐monitored fasting blood glucose was collected throughout the course of the study as referred to elsewhere in this report. Baseline characteristics by efsitora dose group at Week 52 and for glargine (randomised population). Note: Data are mean ± standard deviation unless specified otherwise. Abbreviations: BMI = body mass index, DPP‐4 = dipeptidyl peptidase 4, FSG = fasting serum glucose, GLP‐1 RA = glucagon‐like peptide‐1 receptor agonist, HbA1c = glycosylated haemoglobin, N = number of participants with available dose data at Week 52 for efsitora and overall participants randomised to glargine, SGLT2 = sodium‐glucose cotransporter 2. Race category percentages may not add to 100% as responses of ‘Native Hawaiian/other Pacific Islander’ and ‘Missing’ are not included. FSG was measured at baseline by the central laboratory; self‐monitored fasting blood glucose was collected throughout the course of the study as referred to elsewhere in this report. HbA1c and FBG Outcomes by Dose at Week 52 The magnitude of change in HbA1c was similar for each dose group (Figure 2A; Table S1). Mean HbA1c changes from baseline to Week 52 were as follows: −1.1% (−12.5 mmol/mol) for the 100 U dose subgroup from a baseline of 7.8% (61.4 mmol/mol), −1.3% (−13.7 mmol/mol) for the 150 U dose subgroup from a baseline of 8.0% (64.2 mmol/L), −1.6% (−17.1 mmol/mol) for the 250 U dose subgroup from a baseline of 8.3% (66.8 mmol/mol), −1.4% (−15.3 mmol/mol) for the 400 U subgroup from a baseline of 8.3% (66.7 mmol/mol) and −1.2% (−13.6 mmol/mol) for the > 400 U multi‐dose pen dose subgroup from a baseline of 8.4% (68.3 mmol/mol). HbA1c and FBG from baseline to Week 52. (A and B) Values by efsitora dose subgroups at Week 52. Only those with non‐missing dose information at Week 52 were included. Data are presented as mean. (C and D) Values for participants assigned to efsitora versus glargine. Data are presented as least‐squares mean from a mixed model for repeated measures. FBG = fasting blood glucose; HbA1c = glycosylated haemoglobin. Change in HbA1c from baseline to Week 52 for participants who had a basal insulin dose > 400 U at any time during the study was the same for both efsitora and glargine (−1.2%; −12.6 mmol/mol) and was similar to the change in HbA1c among those who did not exceed an insulin dose of 400 U (efsitora: −1.2% [−12.8 mmol/mol]; glargine: −1.2% [−13.3 mmol/mol]). Self‐measured FBG by efsitora subgroup followed a similar pattern to HbA1c (Figure 2B; Table S1). Mean FBG changes from baseline to Week 52 were as follows: −25 mg/dL (−1.4 mmol/L) for the 100 U dose subgroup, −52 mg/dL (−2.9 mmol/L) for the 150 U subgroup, −62 mg/dL (−3.4 mmol/L) for the 250 U dose subgroup, −69 mg/dL (−3.8 mmol/L) for the 400 U dose subgroup and −65 mg/dL (−3.6 mmol/L) for the > 400 U multi‐dose pen dose subgroup. Decreases in HbA1c and FBG over time were comparable between participants in the efsitora and glargine groups (Figure 2C,D). The percentage of participants who achieved an HbA1c < 7.0% (< 53.0 mmol/mol) at Week 52 was 74% for the 100 U dose subgroup, 67% for the 150 U dose subgroup, 72% for the 250 U dose subgroup, 48% for the 400 U dose subgroup and 51% for the > 400 U multi‐dose pen dose subgroup (Figure 3A). The percentage of participants who achieved an HbA1c of ≤ 6.5% (≤ 47.5 mmol/mol) at Week 52 was 46% for the 100 U dose subgroup, 49% for the 150 U dose subgroup, 44% for the 250 U dose subgroup, 28% for the 400 U dose subgroup and 35% for the > 400 U multi‐dose pen dose subgroup (Figure 3B). The estimated percentages of participants who achieved an HbA1c of < 7.0% (< 53.0 mmol/mol) were 57.4% and 51.5% for the overall efsitora and glargine groups, respectively (Figure 3C). The estimated percentages of participants who achieved an HbA1c of ≤ 6.5% (≤ 47.5 mmol/mol) were 37.0% and 32.7% in the efsitora and glargine groups, respectively (Figure 3D). Proportion of participants achieving HbA1c < 7.0% and ≤ 6.5% at Week 52. (A and B) Estimated percentages of participants by efsitora dose subgroups determined by the participants' efsitora dose at Week 52; only those with non‐missing dose information at Week 52 were included. (C and D) Estimated percentages of participants assigned to efsitora versus glargine. Missing HbA1c values at Week 52 are imputed by the return‐to‐baseline multiple imputation approach. HbA1c = glycosylated haemoglobin. Hypoglycaemia During the First 16 Weeks and Following Dose Increases As previously reported, rates of hypoglycaemia were low throughout the study, including during the first 16 weeks of the study when most of the efsitora fixed‐dose increases occurred [5]. Figure S1 shows the incidence and estimated annualised rate of hypoglycaemia by treatment week for the first 16 weeks of the study. Numbers of hypoglycaemic events remained low throughout this period and appeared similar between the treatment groups. The incidence and rate of hypoglycaemia within the 4‐week period after an efsitora fixed‐dose increase was very low for all fixed‐dose increases (Table 2). The comparative estimated yearly rates of combined Level 2 or 3 hypoglycaemia were 0.26 events per year for the increase from 100 to 150 U (50% dose increase), 0.42 events per year for the increase from 150 to 250 U (67% dose increase) and 0.18 events per year for the increase from 250 to 400 U (60% dose increase). No events were reported for the dose increase from 400 to > 400 U with the multi‐dose pen (Table 2). TABLE 2Hypoglycaemia incidence and rate in 4 weeks after efsitora fixed‐dose change.Number of participants a Incidence in 4 weeks after dose increase, n (%)Hypoglycaemic events in 4 weeks after dose increaseHypoglycaemic event rate 4 weeks after dose increasesEstimated hypoglycaemic event rate/year Level 1 hypoglycaemia Increase from 100 to 150 U (50% increase)32422 (6.8)370.1101.435Increase from 150 to 250 U (67% increase)24718 (7.3)340.1131.474Increase from 250 to 400 U (60% increase)14119 (13.5)440.3124.070Increase of 400 U to multi‐dose pen (> 400 U)897 (7.9)80.0901.174 Combined Level 2 or 3 hypoglycaemia Increase from 100 to 150 U3247 (2.2)70.0200.261Increase from 150 to 250 U2476 (2.4)80.0320.417Increase from 250 to 400 U1412 (1.4)20.0140.183Increase of 400 U to multi‐dose pen (> 400 U)890 (0.0)00.0000.000 Note: Levels of hypoglycaemia severity were Level 1 (hypoglycaemia alert; glucose ≥ 54 and < 70 mg/dL [≥ 3.0 and < 3.9 mmol/L]), Level 2 (clinically significant hypoglycaemia; glucose, < 54 mg/dL [< 3.0 mmol/L]) and Level 3 (severe hypoglycaemia; requiring assistance for treatment). a Number is based on defined dose changes occurring at any time during the study. Hypoglycaemia incidence and rate in 4 weeks after efsitora fixed‐dose change. Note: Levels of hypoglycaemia severity were Level 1 (hypoglycaemia alert; glucose ≥ 54 and < 70 mg/dL [≥ 3.0 and < 3.9 mmol/L]), Level 2 (clinically significant hypoglycaemia; glucose, < 54 mg/dL [< 3.0 mmol/L]) and Level 3 (severe hypoglycaemia; requiring assistance for treatment). Number is based on defined dose changes occurring at any time during the study. Discussion This post hoc subgroup analysis of QWINT‐1 demonstrated that treatment of insulin‐naïve participants with T2D with fixed‐dose titration of once‐weekly efsitora achieved safe and effective glycaemic control at Week 52, regardless of the final fixed‐dose required. Rates of clinically significant or severe hypoglycaemia were low across the study, including in the periods following fixed‐dose escalation. The majority of participants required only a few dose changes, and more than three‐quarters of participants remained on the fixed doses throughout the trial without needing further titration using a multi‐dose pen. Across all fixed doses and the multi‐dose pen, efsitora resulted in robust lowering of HbA1c and FBG. High proportions of those who ended treatment on fixed doses of 100 U, 150 U, or 250 U achieved HbA1c < 7.0% at Week 52. Additionally, following initiation of the first dose, the median number of dose changes during the study was two with efsitora versus eight with glargine [5]. Early experience of the benefits of basal insulin treatment titrated with a simple regimen may make patients more likely to persist with treatment and achieve better glycaemic goals in the long‐term. The convenience and simplicity of the fixed‐dose regimen, along with effective HbA1c lowering across all doses, suggest that this may be a valuable option for people with T2D and their clinicians when initiating and managing insulin therapy, regardless of individual characteristics and insulin needs. Although the majority of participants remained on the fixed doses throughout the study, 24% transitioned to flexible doses of efsitora using the multi‐dose pen based on having a FBG > 130 mg/dL. Per the protocol, participants switched to the multi‐dose pen for doses > 400 U if they had not achieved the target FBG of 80–130 mg/dL after at least 4 weeks on the 400 U fixed‐dose. Those requiring higher efsitora doses likely represent individuals with a more difficult‐to‐treat or more advanced T2D, reflected by their higher baseline BMI and HbA1c and need for more concomitant antihyperglycaemic medications, potentially including prandial insulin. Additionally, it is possible that fewer participants may have required doses > 400 U if the dose titration criteria were based on a broader FBG target or preferably based on HbA1c instead of FBG, as may be common in clinical practice. This may have allowed for continued reductions in HbA1c with the 400 U fixed‐dose, potentially reducing the number of participants who needed to switch to the multi‐dose pen. Concerns around hypoglycaemia in clinical practice significantly contribute to delays in initiating and intensifying insulin therapy [6, 7, 8]. The four fixed doses of 100, 150, 250, and 400 U per week used in the study were equivalent to daily doses of 14 U, 21 U, 36 U, and 57 U, respectively. Given the weekly administration and the size of dose increases, particularly at the higher fixed doses, rates of hypoglycaemia associated with fixed‐dose increases were of particular interest and the results were very reassuring. In QWINT‐1, hypoglycaemia rates were very low throughout the study (< 1 combined Level 2 or 3 events per year) including during the first 16 weeks of the study when most efsitora fixed‐dose increases occurred [5]. Looking at events by week within that period in the present analysis, estimated rates of Level 1 hypoglycaemia and combined Level 2 and 3 hypoglycaemia were low and typically numerically lower for efsitora than glargine throughout. Additionally, the present analysis found that rates of combined Level 2 or 3 hypoglycaemia remained very low in the 4 weeks following dose increases in the efsitora group (< 0.5 estimated events per year). These findings may offer reassurance to clinicians and patients who may be concerned about increasing insulin efsitora fixed doses. However, as with any basal insulin, hypoglycaemia and/or fear of hypoglycaemia is often a limiting factor in advancing basal insulin titration, so continued glucose monitoring and management of recognition and treatment is required. QWINT‐1 was a large, multinational trial which included a range of non‐insulin glucose‐lowering agents, reflective of real‐world clinical practice. The study had high participant retention and well‐balanced treatment groups. This analysis provides important insights into each efsitora dose level. Limitations of this analysis included that the dose subgroups were defined by post‐treatment variables, which can introduce bias through post‐randomisation confounding. Therefore, interpretation is limited to descriptive insights rather than causal conclusions. In addition, there was a relatively high number of missing dose data likely because the dose was self‐reported by participants at the end of a 52‐week treatment period. Furthermore, continuous glucose monitoring was not included in the trial, although this was by design to lower the patient burden for the insulin‐naïve patient population. However, the combined use of continuous glucose monitors with fixed efsitora doses is expected in clinical practice and may even improve further glucose control with less hypoglycaemia. Finally, re‐escalation of efsitora fixed doses after a dose reduction due to hypoglycaemia was not permitted, which does not reflect usual clinical practice but was considered necessary to minimise analytic complexity and for participant safety in an innovative fixed‐dose regimen. In conclusion, as expected, participants with T2D in the QWINT‐1 study who required larger doses of efsitora had greater body weight and higher levels of HbA1c and fasting glucose at baseline. The innovative efsitora fixed‐dose titration regimen resulted in effective HbA1c lowering for participants on all fixed doses. Escalation to higher fixed doses did not result in a high rate of clinically significant or severe hypoglycaemia. The convenience and simplicity of this fixed‐dose approach may be a valuable option for people with T2D and may become a paradigm change in basal insulin management. Author Contributions Julio Rosenstock, Qianqian Wang and Christopher J. Child contributed to the conception and design of the work. Lisa Connery contributed to the acquisition of data. Qianqian Wang and Christopher J. Child contributed to the data analysis. All authors contributed to the interpretation of results. All authors participated in the drafting or critical revision of the manuscript and approved the final version of the manuscript. Funding This study was funded by Eli Lilly and Company. Conflicts of Interest Lisa Connery has received research funding from AbbVie, Achieve, Amag, Amgen, Argo, AstraZeneca, Boehringer Ingelheim, Carmot, Concert, Covalent, Eli Lilly and Company, Esperian, Furiex, Intarcia, Janssen, Kowa, Lexicon, Merck, Mylan, Novartis, Novo Nordisk, Oromed, Otsuka, Pfizer, Regeneron, Regor, Roche, Salix, Scholar Rock, Structure Therapeutics, Vanda, Verdiva, Vertex, Viking, vTv and Zealand; and served on advisory boards for Boehringer Ingelheim, Eli Lilly and Company and Intarcia. Julio Rosenstock has received clinical research grants from Amgen, Applied Therapeutics, AstraZeneca, BioAge, Biomea Fusion, Boehringer Ingelheim, Carmot, Corcept, Eli Lilly and Company, Hanmi, Merck, Novartis, Novo Nordisk, Oramed, Pfizer, Regeneron and Sanofi; scientific advisory board honorarium or consulting fees from Amgen, Applied Therapeutics, Biomea Fusion, Boehringer Ingelheim, Eli Lilly and Company, Hanmi, Novo Nordisk, Oramed, Regeneron, Roche, Sanofi, Structure Therapeutics, Terns Pharmaceuticals and Zealand Pharma; and honoraria from Eli Lilly and Company and Sanofi. Neda Rasouli receives research funding from Eli Lilly and Company and Novo Nordisk and is a consultant for Eli Lilly and Company, Novo Nordisk and Sanofi. Alice Y. Y. Cheng serves as a consultant/advisory board member for Abbott Diabetes Care, Aspen, AstraZeneca, Bayer, Boehringer Ingelheim, Dexcom, Eli Lilly and Company, Gan & Lee, HLS Therapeutics, Insulet, Merck, MSD, Novo Nordisk, Sandoz, Sanofi and Vertex; received speaking honoraria from Abbott Diabetes Care, Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, Dexcom, Eli Lilly and Company, GlaxoSmithKline, HLS Therapeutics, Insulet, Novo Nordisk, Pfizer and Sanofi and works on clinical trials for Applied Therapeutics, Novo Nordisk and Sanofi. Andreas Liebl has received research support and honoraria for giving presentations and attending advisory boards from AstraZeneca, Bayer, Becton Dickinson, Boehringer Ingelheim, Bristol Myers Squibb, Eli Lilly and Company, Medtronic, MSD, Novo Nordisk, Roche and Sanofi. Qianqian Wang, Vitoria Pires, Alastair Knights, Michael B. Davidson and Christopher J. Child are employees and shareholders of Eli Lilly and Company. Supporting information Figure S1: Incidence and estimated annualised rate of hypoglycaemia by week. Table S1: Change from baseline to Week 52 in HbA1c and FBG by efsitora dose subgroup.